Tue, Jan 27, 2015, 7:58 AM EST - U.S. Markets open in 1 hr 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • greatdayforinvestments greatdayforinvestments May 23, 2009 9:18 PM Flag

    Celgene Panzem® (2ME2) for Rheumatoid Arthritis

    Will Celgene partner with EntreMed (ENMD)?:
    "In 2008, we completed a healthy volunteer clinical trial for Panzem® and are currently seeking a development partner to manage larger multi-arm Phase 2 and Phase 3 studies."

    Panzem® (2ME2) for Rheumatoid Arthritis
    Panzem® is an orally active compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. Panzem® attacks tumor cells through multiple mechanisms of action including the inhibition of angiogenesis. Panzem® inhibits production of the transcription factor hypoxia inducible factor-1 alpha (HIF-1α), which is a protein required for angiogenesis and cell survival. The inhibition of angiogenesis is an important approach to the treatment of both cancer and rheumatoid arthritis. Panzem® has potential as a single agent in rheumatoid arthritis based on its antiangiogenic, anti-inflammatory, and anti-osteoclastic (bone resorption) properties.

    We have an IND to develop Panzem® (2-methoxyestradiol, 2ME2) in rheumatoid arthritis (RA) based on its safety profile demonstrated throughout the oncology development effort, and preclinical research results showing that 2ME2 has disease modifying or “DMARD” activity in a variety of animal models of RA. DMARDs are drugs that have the ability to slow down disease progression in rheumatoid arthritis and other autoimmune diseases, in contrast to non-steroidal anti-inflammatory drugs which only treat the immune reaction resulting from tissue damage. We have generated substantial preclinical data demonstrating the positive effects of 2ME2 treatment on inflammation and disease progression in standard animal models of RA. Radiographic and immunohistochemical staining results from these preclinical studies have shown consistent therapeutic effects on the hallmarks of the disease, including the inhibition of the highly angiogenic p@#$%, infiltrating cells, cartilage lesions and bone resorption.

    We believe that a significant opportunity exists for 2ME2 to become a novel, non-immunosuppressive DMARD for the treatment of RA. We are seeking a development partner for 2ME2 in RA. We believe that this opportunity represents a safe, orally administered small molecule alternative to current biologicals and a potential “first in class” opportunity in RA.

    The FDA has accepted our IND for 2ME2 in RA, which included an extensive human safety dossier in 300 patients from the oncology studies. We believe that Panzem® for RA represents a safe, orally-administered, small molecule alternative to current biologicals and a potential “first-in-class” cross-over opportunity from oncology. In 2008, we completed a healthy volunteer clinical trial for Panzem® and are currently seeking a development partner to manage larger multi-arm Phase 2 and Phase 3 studies.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CELG
124.12+0.23(+0.19%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.